Lennette's Laboratory Diagnosis of Viral
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
USMLE – What's It
Purpose of this handout Congratulations on making it to Year 2 of medical school! You are that much closer to having your Doctor of Medicine degree. If you want to PRACTICE medicine, however, you have to be licensed, and in order to be licensed you must first pass all four United States Medical Licensing Exams. This book is intended as a starting point in your preparation for getting past the first hurdle, Step 1. It contains study tips, suggestions, resources, and advice. Please remember, however, that no single approach to studying is right for everyone. USMLE – What is it for? In order to become a licensed physician in the United States, individuals must pass a series of examinations conducted by the National Board of Medical Examiners (NBME). These examinations are the United States Medical Licensing Examinations, or USMLE. Currently there are four separate exams which must be passed in order to be eligible for medical licensure: Step 1, usually taken after the completion of the second year of medical school; Step 2 Clinical Knowledge (CK), this is usually taken by December 31st of Year 4 Step 2 Clinical Skills (CS), this is usually be taken by December 31st of Year 4 Step 3, typically taken during the first (intern) year of post graduate training. Requirements other than passing all of the above mentioned steps for licensure in each state are set by each state’s medical licensing board. For example, each state board determines the maximum number of times that a person may take each Step exam and still remain eligible for licensure. -
Open Research Online Oro.Open.Ac.Uk
Open Research Online The Open University’s repository of research publications and other research outputs The Role of Viral Load in the Pathogenesis of HIV-2 Infection in West Africa Thesis How to cite: Ariyoshi, Koya (1998). The Role of Viral Load in the Pathogenesis of HIV-2 Infection in West Africa. PhD thesis The Open University. For guidance on citations see FAQs. c 1998 Koya Ariyoshi https://creativecommons.org/licenses/by-nc-nd/4.0/ Version: Version of Record Link(s) to article on publisher’s website: http://dx.doi.org/doi:10.21954/ou.ro.000101f4 Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies page. oro.open.ac.uk THE ROLE OF VIRAL LOAD D< THE PATHOGENESIS OF HTV-2 INFECTION IN WEST AFRICA BY KOYAARIYOSHI MRC Laboratories, Fajara, The Gambia, West Africa ^ ew • I A thesis submitted to the Open University in fulfilment for the degree of Doctor of Philosophy 1998 Collaborating Establishments: University College Medical School (London) Statens Serum Institute (Copenhagen) Institute of Molecular Medicine (Oxford) Institute of Cancer Research (London) _ ProQuest Number:C706741 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. -
Cytomegalovirus Infection of the Human Gastrointestinal Tract
Journal of Gastroenterology and Hepatology (1999) 14, 973–976 OESOPHAGOGASTRODUODENAL DISORDERS Cytomegalovirus infection of the human gastrointestinal tract SUSAMA PATRA, SUBASH C SAMAL, ASHOK CHACKO, VADAKENADAYIL I MATHAN1 AND MINNIE M MATHAN1 The Wellcome Trust Research Laboratory, Department of Gastrointestinal Sciences, Christian Medical College and Hospital,Vellore,India Abstract Background: Current interest in cytomegalovirus (CMV) is largely due to an increase in the number of cases of acquired immunodeficiency syndrome and organ transplantation in recent years.The proper recognition of CMV-infected cells in gastrointestinal mucosal biopsies is critical for effective treatment of this condition. Methods: A total of 6580 endoscopic mucosal biopsies from 6323 patients in the 8-year period (1989–1996) were examined for CMV inclusion bodies. The endoscopic appearance and particularly the presence of ulcers were also analysed. Results and Conclusions: The prevalence of cytomegalovirus (CMV) inclusions was 9 per thousand in the gastrointestinal mucosal biopsies from an unselected group of patients. Of the 54 patients with CMV infection, 37 were immunocompromised and 17 apparently immunocompetent. Typical Cowdry inclusions and atypical inclusions were present, the latter more frequently in immunocompromised patients. The maximum prevalence of inclusions was in the oesophageal mucosa in immunocompro- mised individuals. © 1999 Blackwell Science Asia Pty Ltd Key words: cytomegalovirus, gastrointestinal tract, immunocompetent, immunocompromised, inclu- sion bodies, mucosal biopsies. INTRODUCTION in haematoxylin and eosin (HE)-stained histological samples is regarded as being sensitive and specific for Cytomegalovirus (CMV), first described in 1956,1 is a CMV infection,6–9 especially for samples from the gas- double-stranded DNA virus belonging to the herpes trointestinal tract. -
Annual Meeting
Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign. -
Pdfs/ Ommended That Initial Cultures Focus on Common Pathogens, Pscmanual/9Pscssicurrent.Pdf)
Clinical Infectious Diseases IDSA GUIDELINE A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya J. Michael Miller,1 Matthew J. Binnicker,2 Sheldon Campbell,3 Karen C. Carroll,4 Kimberle C. Chapin,5 Peter H. Gilligan,6 Mark D. Gonzalez,7 Robert C. Jerris,7 Sue C. Kehl,8 Robin Patel,2 Bobbi S. Pritt,2 Sandra S. Richter,9 Barbara Robinson-Dunn,10 Joseph D. Schwartzman,11 James W. Snyder,12 Sam Telford III,13 Elitza S. Theel,2 Richard B. Thomson Jr,14 Melvin P. Weinstein,15 and Joseph D. Yao2 1Microbiology Technical Services, LLC, Dunwoody, Georgia; 2Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 3Yale University School of Medicine, New Haven, Connecticut; 4Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland; 5Department of Pathology, Rhode Island Hospital, Providence; 6Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; 7Department of Pathology, Children’s Healthcare of Atlanta, Georgia; 8Medical College of Wisconsin, Milwaukee; 9Department of Laboratory Medicine, Cleveland Clinic, Ohio; 10Department of Pathology and Laboratory Medicine, Beaumont Health, Royal Oak, Michigan; 11Dartmouth- Hitchcock Medical Center, Lebanon, New Hampshire; 12Department of Pathology and Laboratory Medicine, University of Louisville, Kentucky; 13Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts; 14Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, Illinois; and 15Departments of Medicine and Pathology & Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey Contents Introduction and Executive Summary I. -
Maternal Mortality and HIV: an Overview
Maternal Mortality and HIV: An Overview Contextual factors such as local policies and cultural norms, as well as socioeconomic factors, play a role in women’s ability to access care and receive appropriate treatment during pregnancy, childbirth, and postpartum.1 This is true for all women, and particularly so for the 17 million women living with HIV globally, the vast majority of whom live in sub-Saharan Africa (SSA) and are of reproductive age.2 In 2013, HIV was responsible for 1.5% of all maternal Adult HIV prevalence rates, 2012 data from Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. deaths in SSA and 0.4% worldwide.3 Pregnant women living with HIV have between a two to 10 times increased risk of death than uninfected pregnant women.4,5,6,7,8 While maternal deaths have decreased overall in the past decade, countries with high HIV burdens have had slower declines compared to countries less affected by the HIV pandemic. For example, South Africa—an upper middle-income country with an HIV infection rate among pregnant women aged 15-49 years of 29.5%9—experienced a decrease of only 0.4% in its maternal mortality ratio (MMR) between 1990 and Data on maternal mortality ratio (per 100,000 live births) from World 2013, despite a global MMR decrease of 45% in the Health Organization 2012. same timeframe10. CAUSES OF MATERNAL MORBIDITY AND MORTALITY AMONG WOMEN LIVING WITH HIV The World Health Organization (WHO) defines maternal death as “the death of a woman during pregnancy or within 42 days of termination of pregnancy irrespective -
Introduction to the Maternal and Newborn Quality of Care Surveys
INTRODUCTION TO THE MATERNAL AND NEWBORN QUALITY OF CARE SURVEYS Introduction To The Quality of Care Surveys i The Maternal and Child Health Integrated Program (MCHIP) is the United States Agency for International Development’s Bureau for Global Health flagship maternal, neonatal and child health program. MCHIP supports programming in maternal, newborn and child health, immunization, family planning, malaria and HIV/AIDS, and strongly encourages opportunities for integration. Cross-cutting technical areas include water, sanitation, hygiene, urban health and health systems strengthening. This study was made possible by the generous support of the American people through the United States Agency for International Development (USAID), under the terms of the Leader with Associates Cooperative Agreement GHS-A-00-08-00002-00. The contents are the responsibility of the Maternal and Child Health Integrated Program (MCHIP) and do not necessarily reflect the views of USAID or the United States Government. Published by: Jhpiego Brown’s Wharf 1615 Thames Street Baltimore, Maryland 21231-3492, USA January 2013 Introduction To The Quality of Care Surveys ii 1. BACKGROUND Improving the quality of obstetric care in facilities has recently been identified as a neglected and essential approach to reducing maternal deaths and enabling developing countries to achieve Millennium Development Goal (MDG) 4 and 5.1 Postpartum hemorrhage is the most frequent cause of maternal deaths globally and in developing countries, accounting for 25% of maternal deaths. Next are hypertensive disorders in pregnancy (PE/E) at 15%, sepsis (8%) and obstructed labor (7%).2 Effective interventions exist for screening, preventing and treating obstetric and newborn complications, and they can be readily provided by skilled providers in facilities. -
Next-Generation Lab-On-A-Chip Devices
Next-generation lab-on-a-chip devices Samuel Sia, Ph.D. Associate Professor Department of Biomedical Engineering Columbia University APHL, Little Rock June 4, 2014 Clinical ELISA testing... ELISA ideal method low cost? - capital -per test compact? rapid? simple to operate? sensitive (pM)? distinguishes quantitative differences? amenable to parallel analysis? operable without ground electricity? works in field conditions (sunlight)? • coat surface with antigen (overnight) • block with 1% BSA or 0.05% Tween-20 (1 hr) uses accessible • add sample containing antibody to be tested (1 hr) reagents? • add enzyme-conjugated antibody (1 hr) • add substrate (10 min.) “Plug-in cartridge” (bubble-based reagent delivery) 17 pM 170 pM 1.7 nM 17 nM 170 nM 1.7 M Fluorescent antibody Sample Wash Wash Fluorescent Air spacers antibody 200 m Vacuum Antibody in sample Antigen 1200 1000 800 500-m 600 width 250-m 400 50-m width width total time = 2 min. 200 500-m (hands-free) width 0 Normalized fluorescence (a.u.) fluorescence Normalized 0.1 10 1000 Concentration of anti-rabbit IgG (nM) Linder, Sia, and Whitesides, Anal. Chem., 77:64 (2005) Silver reduction enables the use of microfluidics Angew Chemie, 43:498 (2004) ELISA mChip signal generation enzyme/substrate silver precipitation reaction (photography) light source lasers, lenses, filters LEDs (ambient lighting) detector photomultiplier tubes photodetector (photocopier) manufacturing plastic 96-well plates injection-molded plastic (consumer toys) Point-of-care ELISA Founded in 2004 (with Vincent Linder and David Steinmiller), based in Boston area raised ~$12M in VC funding First product: prostate cancer monitoring ISO-certified manufacturing facility and clean room approved in Europe (CE Mark) acquired by Opko Health in 2011 (~$50M) awaiting FDA approval and launch of PSA test and eventually 4K panel (total PSA, free PSA, intact PSA, HK2) Clinical scenario Pregnant woman in high burden-of-disease area (health clinic in U.S. -
Principle of Infection
23/09/56 Principle of Infection La-or Chompuk, M.D. Department of pathology Faculty of Medicine Infection • Definition: Invasion and multiplication of microorganisms in body tissues • No symptom, local cellular injury, localized symptom, dissemination • Mechanism; competitive metabolism, toxins, intracellular replication, immune response 1 23/09/56 Classification of infectious agents: - classification according to structure - classification according to pathogenesis - classification according to site of multiplication Classification according to structure - Prion - Fungi - Viruses - Protozoa, metazoa - Bacteria - Ectoparasite - Rickettsia, chlamydia, mycoplasma 2 23/09/56 Classification according to pathogenesis • Pathogenic agents; - Virulence: the degree of pathogenicity of a microorganism - Indicated by the severity of disease, the ability to invade tissue - high virulence - low virulence • Opportunistic infection Classification according to site of multiplication - obligate intracellular organisms; Prions, viruses, rickettsiae, chlamydia, some protozoa - facultative intracellular organism; Mycobacteria, Actinomyces, Pseudomonas spp. - extracellular organisms; mycoplasma, fungi, bacteria, metazoa 3 23/09/56 Pathogenesis of Infectious Disease -Host - Pathogen; organism or parasite that cause disease Host factors: 1. General factors; socioeconomic status, behavior pattern, occupational, and internal factors 2. Natural defense mechanism; skin and normal flora, respiratory tract and mucociliary mechanism, Hcl production in stomach, or -
Herpes Simplex Virus-Associated Dermatitis with Either High Or Normal Ige Responded Well to Antiviral Therapy: a Study of 787 Quick-Tzanck-Test-Positive Patients
Article ID: WMC004846 ISSN 2046-1690 Herpes Simplex Virus-Associated Dermatitis with Either High or Normal IgE Responded Well to Antiviral Therapy: A Study of 787 Quick-Tzanck-Test-Positive Patients Peer review status: No Corresponding Author: Dr. Lily Hsiao, Vice president, Moriya Eye and Skin Clinic, 5-7-1, Mizukino, 302-0121 - Japan Submitting Author: Dr. Lily Hsiao, Vice president, Moriya Eye and Skin Clinic, 5-7-1, Mizukino, 302-0121 - Japan Article ID: WMC004846 Article Type: Original Articles Submitted on:20-Mar-2015, 07:33:49 AM GMT Published on: 20-Mar-2015, 07:34:27 AM GMT Article URL: http://www.webmedcentral.com/article_view/4846 Subject Categories:DERMATOLOGY Keywords:herpes simplex virus, quick Tzanck test, erythema multiforme, atopic dermatitis, intrinsic atopic dermatitis How to cite the article:Hsiao L. Herpes Simplex Virus-Associated Dermatitis with Either High or Normal IgE Responded Well to Antiviral Therapy: A Study of 787 Quick-Tzanck-Test-Positive Patients. WebmedCentral DERMATOLOGY 2015;6(3):WMC004846 Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Source(s) of Funding: None Competing Interests: None Additional Files: HSVADWMC15 WebmedCentral > Original Articles Page 1 of 33 WMC004846 Downloaded from http://www.webmedcentral.com on 20-Mar-2015, 07:38:29 AM Herpes Simplex Virus-Associated Dermatitis with Either High or Normal IgE Responded Well to Antiviral Therapy: A Study of 787 Quick-Tzanck-Test-Positive Patients Author(s): Hsiao L Abstract Abbreviations Background: The overall age-adjusted 1. -
Prevention and Control of Malaria in Pregnancy in the African Region
P R E V E N T I O N A N D C O N T R O L O F M A L A R I A I N PREGNANC Y I N THE A FRIC AN R EGION A Program Implementation Guide P R E V E N T I O N A N D C O N T R O L O F M A L A R I A I N PREGNANC Y I N THE A FRIC AN R EGION A Program Implementation Guide For information: Jhpiego 1615 Thames Street Baltimore, MD 21231-3492, USA Tel: 410.537.1800 www.jhpiego.org Editor: Ann Blouse Graphic Design: Trudy Conley The ACCESS Program is the U.S. Agency for International Developments global program to improve maternal and newborn health. The ACCESS Program works to expand coverage, access and use of key maternal and newborn health services across a continuum of care from the household to the hospitalwith the aim of making quality health services accessible as close to the home as possible. Jhpiego implements the program in partnership with Save the Children, the Futures Group, the Academy for Educational Development, the American College of Nurse- Midwives and IMA World Health. www.accesstohealth.org Jhpiego is an international, non-profit health organization affiliated with The Johns Hopkins University. For nearly 40 years, Jhpiego has empowered front-line health workers by designing and implementing effective, low-cost, hands-on solutions to strengthen the delivery of health care services for women and their families. By putting evidence-based health innovations into everyday practice, Jhpiego works to break down barriers to high-quality health care for the worlds most vulnerable populations. -
New and Emerging Yeast Pathogens KEVIN C
CLINICAL MICROBIOLOGY REVIEWS, Oct. 1995, p. 462–478 Vol. 8, No. 4 0893-8512/95/$04.0010 Copyright q 1995, American Society for Microbiology New and Emerging Yeast Pathogens KEVIN C. HAZEN* Division of Clinical Microbiology, Department of Pathology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908 INTRODUCTION .......................................................................................................................................................462 DEFINITION OF NEW OR EMERGING YEAST PATHOGENS ......................................................................462 WHICH YEASTS ARE NEW OR EMERGING PATHOGENS? .........................................................................463 ANATOMIC SITES ATTACKED BY YEASTS.......................................................................................................464 HISTOPATHOLOGY .................................................................................................................................................466 TREATMENT OF INFECTIONS DUE TO UNUSUAL YEASTS .......................................................................466 Catheter Removal ...................................................................................................................................................466 Antifungal Therapy.................................................................................................................................................469 MICROBIOLOGICAL IDENTIFICATION ............................................................................................................469